Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
302 questions in 48 reviews · Neuromuscular
current versionsNo studies 302 · 100%Ungraded 0 · 0%Very low 0 · 0%Low 0 · 0%Moderate 0 · 0%High 0 · 0%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Methotrexate and azathioprine vs methotrexate (plus leucovorin) Change in muscle strength at 12 months (%) (using MMT or QMT) at 12 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and azathioprine vs methotrexate (plus leucovorin) Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and azathioprine vs methotrexate (plus leucovorin) Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Methotrexate and azathioprine vs methotrexate (plus leucovorin) Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs placebo Change in muscle mass at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Oxandrolone vs placebo Change in muscle strength at 12 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Oxandrolone vs placebo Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Oxandrolone vs placebo Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Oxandrolone vs placebo Significant adverse events · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs placebo Change in handgrip strength at 6 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Intravenous immunoglobulin vs placebo Change in timed walk at 6 months (%) e.g. 10‐metre or 6‐minute walk test at 6 months ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Interferon beta‐1a vs placebo Change in muscle strength at 12 months (%) ‐ not measured · people with inclusion body myositis Treatment for inclusion body myositis (2015) · Cochrane | no estimate extracted | NR | No studies |
Plasma exchange vs sham exchange Serious adverse events ‐ not measured · people with CIDP Plasma exchange for chronic inflammatory demyelinating polyradiculoneuropathy (2015) · Cochrane | no estimate extracted | NR | No studies |
Plasma exchange (PE) vs sham exchange Change in sensation using a validated scale (e.g. INCAT sensory sum score) ‐ not measured · people with IgG and IgA paraproteinaemic neuropathy Treatment for IgG and IgA paraproteinaemic neuropathy (2015) · Cochrane | no estimate extracted | NR | No studies |
Plasma exchange (PE) vs sham exchange Adverse events ‐ not reported · people with IgG and IgA paraproteinaemic neuropathy Treatment for IgG and IgA paraproteinaemic neuropathy (2015) · Cochrane | no estimate extracted | NR | No studies |
Amantadine vs placebo Activity limitations ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Prednisone vs placebo Activity limitations ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Muscle strengthening vs control Activity limitations ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation in cold climate vs usual care Adverse events ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Rehabilitation in warm climate vs usual care Adverse events ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Static magnetic fields vs placebo Activity limitations ‐ not measured · people with postpolio syndrome Treatment for postpolio syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs placebo Number of patients with self reported pain relief of 50% or greater (not measured) · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Methylprednisolone vs placebo Number of patients with self reported pain relief of 50% or greater (not measured) · patients with Guillain‐Barré syndrome, with varying severities of pain Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Gabapentin vs carbamazepine Number of patients with self reported pain relief of 50% or greater (not measured) · intensive care unit in India Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Carbamazepine vs placebo Number of patients with self reported pain relief of 50% or greater (not measured) · patients with pain in Guillain‐Barré syndrome Pharmacological treatment for pain in Guillain‐Barré syndrome (2015) · Cochrane | no estimate extracted | NR | No studies |
Volume‐cycled ventilation vs pressure‐cycled ventilation Unplanned admission to hospital ‐ not measured · patients with neuromuscular and chest wall disorders and chronic hypoventilation Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall… (2014) · Cochrane | no estimate extracted | NR | No studies |
Volume‐cycled ventilation vs pressure‐cycled ventilation No improvement of hypoventilation symptoms: long‐term ‐ not measured · patients with neuromuscular and chest wall disorders and chronic hypoventilation Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall… (2014) · Cochrane | no estimate extracted | NR | No studies |
Volume‐cycled ventilation vs pressure‐cycled ventilation No improvement of daytime hypercapnia: long‐term ‐ not measured · patients with neuromuscular and chest wall disorders and chronic hypoventilation Nocturnal mechanical ventilation for chronic hypoventilation in patients with neuromuscular and chest wall… (2014) · Cochrane | no estimate extracted | NR | No studies |
Intranasal neostigmine vs placebo Change in impairment 1 to 14 days after the start of treatment ‐ not reported · people with myasthenia gravis Acetylcholinesterase inhibitor treatment for myasthenia gravis (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · patients with the chronic pain of fibromyalgia Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Mean improvement in Patient Reported Global Impression of Change at 12 weeks or less · patients with pain in major depressive disorder Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia (2014) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · patients with pain in major depressive disorder Duloxetine for treating painful neuropathy, chronic pain or fibromyalgia (2014) · Cochrane | no estimate extracted | NR | No studies |
Ascorbic acid vs placebo Change in participation 12 or more weeks after commencement of intervention (not measured) · people with fatigue in peripheral neuropathy Interventions for fatigue in peripheral neuropathy (2014) · Cochrane | no estimate extracted | NR | No studies |
Amantadine vs placebo Change in fatigue 12 or more weeks after commencement of intervention (not measured) · people with fatigue in Guillain‐Barré syndrome Interventions for fatigue in peripheral neuropathy (2014) · Cochrane | no estimate extracted | NR | No studies |
Amantadine vs placebo Change in activity limitation 12 or more weeks after commencement of intervention (not measured) · people with fatigue in Guillain‐Barré syndrome Interventions for fatigue in peripheral neuropathy (2014) · Cochrane | no estimate extracted | NR | No studies |
Amantadine vs placebo Health related quality of life after 12 or more weeks or more after commencement of intervention (not reported) · people with fatigue in Guillain‐Barré syndrome Interventions for fatigue in peripheral neuropathy (2014) · Cochrane | no estimate extracted | NR | No studies |
Ascorbic acid vs placebo Reduction in fatigue of at least 1 point on the Fatigue Severity Scale (FSS) between 4 to 12 weeks after commencement of intervention (not measured) · people with fatigue in peripheral neuropathy Interventions for fatigue in peripheral neuropathy (2014) · Cochrane | no estimate extracted | NR | No studies |
Proparacaine hydrochloride 0.5% eye drops vs placebo 50% pain reduction 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia Non‐antiepileptic drugs for trigeminal neuralgia (2013) · Cochrane | no estimate extracted | NR | No studies |
Proparacaine hydrochloride 0.5% eye drops vs placebo Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia Non‐antiepileptic drugs for trigeminal neuralgia (2013) · Cochrane | no estimate extracted | NR | No studies |
Tizanidine vs carbamazepine 50% pain reduction 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia Non‐antiepileptic drugs for trigeminal neuralgia (2013) · Cochrane | no estimate extracted | NR | No studies |
Tizanidine vs carbamazepine Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia Non‐antiepileptic drugs for trigeminal neuralgia (2013) · Cochrane | no estimate extracted | NR | No studies |
Tocainide vs carbamazepine 50% pain reduction 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia Non‐antiepileptic drugs for trigeminal neuralgia (2013) · Cochrane | no estimate extracted | NR | No studies |
Tocainide vs carbamazepine Quality of life assessment 12 weeks after the start of treatment Not measured · patients with trigeminal neuralgia Non‐antiepileptic drugs for trigeminal neuralgia (2013) · Cochrane | no estimate extracted | NR | No studies |
Topiramate 200 to 400 mg vs placebo Proportion below 30/100 mm on VAS · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy) Topiramate for neuropathic pain and fibromyalgia in adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Topiramate 200 to 400 mg vs placebo Death · neuropathic pain (two studies found in painful diabetic neuropathy, and one in lumbar radiculopathy) Topiramate for neuropathic pain and fibromyalgia in adults (2013) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Other adverse events · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Adverse events · patients with diabetic neuropathy Enhanced glucose control for preventing and treating diabetic neuropathy (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Proportion below 30/100 mm on VAS · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Intervention NR Quality of life measure · painful diabetic neuropathy Lacosamide for neuropathic pain and fibromyalgia in adults (2012) · Cochrane | no estimate extracted | NR | No studies |
Ergonomic keyboard vs placebo Short‐term overall improvement ‐ not measured · people with carpal tunnel syndrome Ergonomic positioning or equipment for treating carpal tunnel syndrome (2012) · Cochrane | no estimate extracted | NR | No studies |